Form 4: iRhythm Officer Acquires Shares via ESPP

iRhythm Technologies' Chief Medical/Scientific Officer, Minang Turakhia, acquired 250 shares of common stock through the company's Employee Stock Purchase Plan.

Summary

• Minang Turakhia, Chief Medical/Scientific Officer and EVP Advanced Technology at iRhythm Technologies, Inc. (IRTC), acquired shares.
• The transaction involved the acquisition of 250 shares of iRhythm Technologies' common stock.
• The shares were acquired at a price of $74.715 per share.
• The acquisition occurred on November 28, 2025, as part of the company's 2016 Employee Stock Purchase Plan (ESPP).
• This purchase was for the period from June 1, 2025, through November 30, 2025.
• Following this transaction, Mr. Turakhia beneficially owns 41,643 shares of common stock directly.
• The transaction is exempt from Section 16(b) under Rule 16b-3.

Sentiment

Score: 7

Explanation: The acquisition of shares by an executive through an ESPP is generally a positive signal of confidence in the company, though it's a routine transaction rather than a discretionary open-market purchase. It reflects alignment of interests but doesn't indicate extraordinary news.

Positives

• An executive acquiring shares through an ESPP can signal confidence in the company's future performance.
• The transaction is part of a pre-established employee benefit plan, indicating routine insider activity and alignment of interests.

Future Outlook

This filing does not contain specific forward-looking statements or guidance, as it primarily reports a past insider transaction.

Management Comments

• Mr. Turakhia is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Issuer's 2016 Employee Stock Purchase Plan for the purchase period June 1, 2025 through November 30, 2025.

Industry Context

Insider purchases, especially through an ESPP, are generally viewed as a positive signal of management's belief in the company's long-term prospects within the medical technology sector. This routine transaction does not indicate any significant shift in broader industry trends or competitive landscape.

Comparison to Industry Standards

• Employee Stock Purchase Plans (ESPPs) are a common benefit offered by publicly traded companies across various industries, including medical technology, to encourage employee ownership and align interests with shareholders. The acquisition of shares by an executive through such a plan is a standard practice and does not inherently suggest outperformance or underperformance compared to industry peers.
• Companies like Medtronic (MDT) and Abbott Laboratories (ABT) also offer similar employee stock purchase programs, where executives and employees can acquire company stock, often at a discount, reflecting a common corporate governance and compensation strategy.

Stakeholder Impact

• Shareholders: The acquisition by an officer may be viewed positively as it aligns management's interests with shareholders, potentially signaling confidence in future performance.
• Employees: The transaction highlights the existence and utilization of the company's Employee Stock Purchase Plan, which is a benefit for eligible employees.

Next Steps

• No specific future actions or milestones are mentioned in this Form 4 filing, which is solely for reporting a past transaction.

Key Dates

Recommendation

This Form 4 filing reports a routine insider acquisition of shares through an Employee Stock Purchase Plan (ESPP). While it indicates an executive's continued participation and alignment with shareholder interests, it is not a discretionary open-market purchase and typically does not provide new fundamental information to warrant a change in investment recommendation. The transaction is expected and part of a pre-existing plan, thus maintaining a 'hold' recommendation is appropriate based solely on this filing.

Keywords

iRhythm Technologies, IRTC, Minang Turakhia, Form 4, Insider Trading, Stock Purchase, ESPP, Employee Stock Purchase Plan, Officer Stock Acquisition